RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine San. Tic. A.Ş., focused on research, development and production of in-vitro diagnostics and biological pharmaceuticals (vaccination) since 1996, started being traded on Borsa İstanbul Second National Market with the ticker code “RTALB” today.

RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine San. Tic. A.Ş., focused on imports and distribution of in-vitro diagnostics and biological pharmaceuticals (vaccination) for animals and production of medical products, started being traded on Borsa İstanbul Second National Market on June 2, 2014. To mark the event, a bell-ringing ceremony was held at Borsa İstanbul with the participation of Borsa İstanbul Executive Vice President Mustafa Kemal Yılmaz and RTA Laboratuvarları Chairman & CEO Reşat Ultav.

RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine San. Tic. A.Ş. offered 33.90% of its shares to the public at a price of TL 13. The ticker code for the Company is “RTALB”.

“With RTA Laboratuvarları, the number of companies traded on Borsa İstanbul has reached 421”

In his speech at the ceremony, Borsa İstanbul Executive Vice President Mustafa Kemal Yılmaz said, “In the first five months of 2014, a total of 5 companies including RTA Laboratuvarları A.Ş. and 2 companies on the Emerging Companies Market were offered to the public, in addition to 177 debt securities, generating a total of TL 25 billion. With RTA Laboratuvarları, the number of companies traded on Borsa İstanbul has reached 421”.